HOUSE_OVERSIGHT_025889.jpg
1.75 MB
Extraction Summary
3
People
8
Organizations
1
Locations
1
Events
3
Relationships
2
Quotes
Document Information
Type:
Article excerpt / webpage printout
File Size:
1.75 MB
Summary
This document discusses the approval, benefits, and high cost of a new cholesterol-lowering drug called Praluent, noting its potential expense concerns raised by CVS Caremark executive Troy Brennan. It details the FDA's approval criteria, focusing on patients with genetic conditions or previous heart disease, and mentions the pricing strategy by Regeneron and Sanofi amidst competition from Amgen. The bottom half of the page lists "Recommended by Forbes" article links.
People (3)
| Name | Role | Context |
|---|---|---|
| Nissen | ||
| Troy Brennan | ||
| Donald Trump |
Organizations (8)
| Name | Type | Context |
|---|---|---|
| Cleveland Clinic | ||
| CVS Caremark | ||
| Amgen | ||
| FDA | ||
| Regeneron | ||
| Sanofi | ||
| Forbes | ||
Timeline (1 events)
FDA clearing Praluent
Locations (1)
| Location | Context |
|---|---|
Relationships (3)
→
→
→
→
→
→
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document